ArticleIJID regions2026
Liposomal amphotericin B-associated electrolyte abnormalities among adult patients in a tertiary hospital.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the possible electrolyte imbalances that can occur with the use of liposomal amphotericin B (L-AMB) among adult patients admitted to Sultan Qaboos University Hospital (SQUH). Methods: A retrospective observational study evaluating clinical characteristics, usage patterns, and electrolyte changes in 94 patients who received L-AMB during their admission at SQUH over 10 years (2015-2025). Results: The majority were male patients with cancer with a median age of 38.5 years, many presenting with sepsis and receiving empiric L-AMB therapy at an median dose of 5 mg/kg daily. Hydration prior to L-AMB initiation was common (74.5%), primarily using normal saline and dextrose. Treatment with L-AMB was associated with a significant decline in potassium and calcium and a rise in sodium levels. Conclusion: L-AMB therapy is associated with significant and clinically meaningful electrolyte disturbances, most prominently progressive hypokalemia. Higher dose per kilogram and pre-infusion hydration were independently associated with hypokalemia. Patients with cancer present with lower baseline electrolytes and are at compounded risk. These findings reinforce the need for structured electrolyte monitoring protocols and early supplementation strategies in all patients receiving L-AMB, particularly those with malignancy or receiving higher drug doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.